Drug intelligence / Profile preview

insulin aspart biosimilar GP40071

Development stage: Phase 3
Lead developer: Geropharm
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

GP40071 is a biosimilar of insulin aspart, a short-acting insulin analogue used to control postprandial glycemia levels in diabetic patients. It is developed by GEROPHARM as part of their biosimilar clinical development program. Clinical trials have demonstrated bioequivalence, similar pharmacodynamics, and comparable safety profiles between GP40071 and the reference product NovoRapid® (Novo Nordisk). The drug works by lowering levels of glucose in the blood, starting to work about 15 minutes after injection, peaking in about 1 hour, and keeping working for 2 to 4 hours.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin aspart biosimilar GP40071.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin aspart biosimilar GP40071.

Explore the full profile